Hormonal agent for skin treatment
    1.
    发明授权
    Hormonal agent for skin treatment 失效
    皮肤治疗激素剂

    公开(公告)号:US06225299B1

    公开(公告)日:2001-05-01

    申请号:US09219660

    申请日:1998-12-23

    IPC分类号: A61K3156

    摘要: The pharmaceutical composition, especially for treating skin with seborrhea, Acne vulgaris and androgonically conditioned alopecia, contains a hormonal agent including the gestogen, dienogest, or a combination of dienogest and an estrogen, as active ingredient. Methods for treatment of this type of skin condition include topical application of the composition including the dienogest which results in an outstanding sebosuppression, a drastic reduction of androstandiol glucuronide and a moderate competitive blockage of androgen receptor sites. Galenic formulations are described which limit and/or prevent the permeation of the active ingredient through the skin. The pharmaceutical preparation including the dienogest and conventional dermatologically acceptable carrier and auxiliary substances in the described galenic formulation advantageously provides a drastic reduction in androstandiol glucuronide and moderate androgen receptor blockage without passing through the skin barrier so that systemic effects including side reactions are substantially prevented.

    摘要翻译: 药物组合物,特别是用于治疗皮脂溢,皮肤寻常痤疮和阴道调理性脱发的皮肤,含有激素剂,包括睾酮,依那诺或二烯酸和雌激素的组合作为活性成分。 用于治疗这种类型皮肤病症的方法包括局部应用组合物,其包括引起明显的抑制作用的替奈格明,葡萄糖醛酸葡萄糖醛酸葡聚糖和葡萄糖醛酸葡聚糖的剧烈降低以及雄激素受体位点的适度竞争性阻断。 描述了限制和/或防止活性成分渗透皮肤的Galenic制剂。 在所述盖仑制剂中包含地那烯酸和常规皮肤病学可接受的载体和辅助物质的药物制剂有利地提供了葡萄糖醛酸葡萄糖醛酸葡萄糖苷和中和雄激素受体阻断物的急剧降低,而不会通过皮肤屏障,从而基本上防止包括副反应的全身效应。

    Hormonal agent for skin treatment
    2.
    发明授权
    Hormonal agent for skin treatment 失效
    皮肤治疗激素剂

    公开(公告)号:US5910493A

    公开(公告)日:1999-06-08

    申请号:US714463

    申请日:1996-09-16

    摘要: The pharmaceutical composition, especially for treating skin with seborrhea, Acne vulgaris and androgonically conditioned alopecia, contains a hormonal agent including the gestogen, dienogest, or a combination of dienogest and an estrogen, as active ingredient. Methods for treatment of this type of skin condition include topical application of the composition including the dienogest which results in an outstanding sebosuppression, a drastic reduction of androstandiol glucuronide and a moderate competitive blockage of androgen receptor sites. Galenic formulations are described which limit and/or prevent the permeation of the active ingredient through the skin. The pharmaceutical preparation including the dienogest and conventional dermatologically acceptable carrier and auxiliary substances in the described galenic formulation advantageously provides a drastic reduction in androstandiol glucuronide and moderate androgen receptor blockage without passing through the skin barrier so that systemic effects including side reactions are substantially prevented.

    摘要翻译: 药物组合物,特别是用于治疗皮脂溢,皮肤寻常痤疮和阴道调理性脱发的皮肤,含有激素剂,包括睾酮,依那诺或二烯酸和雌激素的组合作为活性成分。 用于治疗这种类型皮肤病症的方法包括局部应用组合物,其包括引起明显的抑制作用的替奈格明,葡萄糖醛酸葡萄糖醛酸葡聚糖和葡萄糖醛酸葡聚糖的剧烈降低以及雄激素受体位点的适度竞争性阻断。 描述了限制和/或防止活性成分渗透皮肤的Galenic制剂。 在所述盖仑制剂中包含地那烯酸和常规皮肤病学可接受的载体和辅助物质的药物制剂有利地提供了葡萄糖醛酸葡萄糖醛酸葡萄糖苷和中和雄激素受体阻断物的急剧降低,而不会通过皮肤屏障,从而基本上防止包括副反应的全身效应。